Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last --
Change Today 0.00 / 0.00%
Volume 0.0
FSXMF On Other Exchanges
Symbol
Exchange
Continuous
OTC US
Berlin
All times are local (Market data is delayed by at least 15 minutes).

faes farma sa (FSXMF) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
247.9M
EX-Date
07/1/15
P/E TM
--
Dividend
$0.09
Dividend Yield
--
Current Stock Chart for FAES FARMA SA (FSXMF)

Related News

No related news articles were found.

faes farma sa (FSXMF) Related Businessweek News

No Related Businessweek News Found

faes farma sa (FSXMF) Details

Faes Farma, S.A. engages in the research, development, manufacture, market, and sale of pharmaceutical products; and raw materials for pharmaceutical use worldwide. The company offers prescription, OTC, and skin-care treatment products. It provides cardiovascular products, such as Drosmina, Hyflon, Venosmil, Venosmil Gel, and Venula; central nervous system products, including Colme, Surmenalit, and Trausan; dermatology products comprising Positón; digestive products, such as Mecolzine; metabolism products, including Dynamogen, Ferroprotina, and Potenciator; Locomotor products comprising Defal, Distem, Dolotren, and Dolotren gel; Bilaxten and Bilidren for allergy; and respiratory products, such as Bronquidiazina CR and Yendol. The company also offers raw materials, including diosmin, hidrosmin, magnesium pidolate, arginine aspartate, granulated diosmin, glutodine, trimethropim, and pyrrolidone carboxylate. In addition, it develops Bilastine, an antihistamine, which is in Phase III clinical trials; F-97013-GD, an atypical antipsychotic that is in pre-clinical phase; F-98214-TA, an antidepressant, which is in pre-clinical phase; and serotonin reuptake inhibitors. Faes Farma, S.A. was founded in 1933 and is headquartered in Bilbao, Spain.

Founded in 1933

faes farma sa (FSXMF) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

faes farma sa (FSXMF) Key Developments

Faes Farma and Eddingpharm Form Joint Venture in China

Faes Farma has signed a deal with Eddingpharm (Hong Kong) for the establishment of a joint venture that allows the Spanish company to market its products in the Chinese market. Under the terms of the agreement, the products will be manufactured in Faes Farma plants and exported to China. The project is being initiated with local development and registration of four Faes Farma products in China.

Faes Farma, S.A., Annual General Meeting, Jun 23, 2015

Faes Farma, S.A., Annual General Meeting, Jun 23, 2015. Location: Avda. Abandoibarra, 4 Bilbao.

Faes Farma, S.A. Announces Earnings Results for the Year Ended December 2014

Faes Farma, S.A. announced earnings results for the year ended December 2014. For the year, the company's total revenues were EUR 198.1 million compared with EUR 193.3 million a year ago. The increase in the company's sales has mainly relied on the revenues obtained from Bilastine's licences linked to the fulfillment of certain milestones, on the positive development of the international business (exports grew by 24%) and animal nutrition, as well as on sales of the products marketed over the last years (specially Bilaxten and the anti-diabetic and anti-inflammatory licences) and the catalogue of mature products. EBITDA was EUR 42.2 million compared with EUR 36.2 million a year ago, helped by the increase in sales and the cost containment. EBIT was EUR 33.3 million compared with EUR 25.8 million a year ago. Profit before tax was EUR 32.8 million compared with EUR 24.2 million a year ago. Net profit was EUR 25.3 million compared with EUR 22.6 million a year ago. As on December 2014, the company's net debt was EUR 21 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FSXMF:US $0.00 USD 0.00

FSXMF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Recordati SpA €20.63 EUR -0.02
Shire PLC 5,615 GBp +10.00
Procter & Gamble Co/The $80.23 USD +0.26
View Industry Companies
 

Industry Analysis

FSXMF

Industry Average

Valuation FSXMF Industry Range
Price/Earnings 23.7x
Price/Sales 3.2x
Price/Book 2.7x
Price/Cash Flow 20.2x
TEV/Sales 3.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FAES FARMA SA, please visit www.faes.es. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.